| __timestamp | Genmab A/S | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 505679000 | 7459000 |
| Thursday, January 1, 2015 | 487656000 | 11831000 |
| Friday, January 1, 2016 | 660876000 | 25705000 |
| Sunday, January 1, 2017 | 874278000 | 46181000 |
| Monday, January 1, 2018 | 1431159000 | 59497000 |
| Tuesday, January 1, 2019 | 2386000000 | 65003000 |
| Wednesday, January 1, 2020 | 3137000000 | 74506000 |
| Friday, January 1, 2021 | 4181000000 | 126006000 |
| Saturday, January 1, 2022 | 5562000000 | 126215000 |
| Sunday, January 1, 2023 | 7630000000 | 120161000 |
| Monday, January 1, 2024 | 9748000000 |
Cracking the code
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Genmab A/S has demonstrated a robust increase in R&D investment, growing by over 1,400% from 2014 to 2023. This Danish biotech giant has consistently prioritized R&D, with expenditures peaking at approximately $7.63 billion in 2023. In contrast, Protagonist Therapeutics, Inc., a smaller player in the field, has shown a steady yet modest increase in R&D spending, reaching around $120 million in the same year. This disparity highlights the differing scales and strategies of these companies. While Genmab's aggressive investment reflects its ambition to lead in the biotech sector, Protagonist's more measured approach suggests a focus on sustainable growth. These trends underscore the diverse strategies within the biotech industry, where innovation is key to success.
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Genmab A/S
R&D Insights: How GSK plc and Protagonist Therapeutics, Inc. Allocate Funds
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Research and Development: Comparing Key Metrics for Genmab A/S and Summit Therapeutics Inc.
Analyzing R&D Budgets: Genmab A/S vs Celldex Therapeutics, Inc.
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Protagonist Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development Expenses Breakdown: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending